BadrulAlamChowdhuryMD

Allergy & Immunology • Washington, DC

Physician

Join to view full profile

Are you Dr. Chowdhury?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
6900 Georgia Ave., Pod 1j
Dept Of Allergy And Immunology, Wramc
Washington, DC 20307
Phone+1 202-782-9461

Summary

Dr. Badrul Chowdhury, MD is an allergist/immunologist in Washington, District of Columbia. He is currently licensed to practice medicine in District of Columbia, Pennsylvania, and Tennessee.

Education & Training

National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1991 - 1994
Wayne State University School of MedicineResidency, Internal Medicine, 1988 - 1991
Dhaka Medical CollegeClass of 1982

Certifications & Licensure

MD State Medical License 1989 - 2026
DC State Medical License 1998 - 2022
PA State Medical License 1998 - 2002
MI State Medical License 1990 - 2000
TN State Medical License 1995 - 1999

Publications & Presentations

PubMed

6 citations
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients
Youwei Bi, Dinko Rekić, Miya O Paterniti, Jianmeng Chen, Anshu Marathe
Journal of Pharmacokinetics and Pharmacodynamics. 2021-02-01
15 citations
Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective
Qing Liu, Mohammad Absar, Bhawana Saluja, Changning Guo, Badrul A. Chowdhury
The AAPS Journal. 2019-01-07
10 citations
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease
Robert N. Schuck, Janet Woodcock, Issam Zineh, Peter Stein, Jonathan P. Jarow
Clinical Pharmacology and Therapeutics. 2018-08-01

Press Mentions

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) TrialJune 30th, 2021
Savara Reports First Quarter 2021 Financial Results and Provides Business UpdateMay 13th, 2021
Savara Provides Pipeline and Business UpdateDecember 10th, 2020
Join now to see all